Proven leaders and world-class medical, science, technology and business experts.
Rosemary Elliston is a well-respected healthcare executive and serves as Chief Operations Officer at Bloom Health Partners. A dedicated and effective operator, Rosemary brings a diverse healthcare and IT operations leadership background. She is an engaging relationship builder with expertise in organizational planning, team development, multimillion-dollar capital projects, and increasing visibility for growth.
Prior to working with Bloom, she served as Chief Client and Operations Officer at International Capital and Management Company – ICMC, where she led an exceptional stakeholder team providing inventive solutions and expanding business capabilities to Cancer Treatment Centers of America. Rosemary has led multiple highly visible projects and teams with industry leaders such as Kaiser Permanente, Andersen Consulting, Perot Systems and Blue Cross Blue Shield. She maintains an active PMP certification and engagement in the Project Management Institute. Rosemary majored in Medical Technology at the University of South Alabama in Mobile, AL and is an alumna of the Executive Development Program from The Wharton School of the University of Pennsylvania.
Her passions away from work include traveling, family time, outdoor activities, and cooking. She volunteers her time in community outreach with organizations such as Patient Assist VI, Susan G. Koman, United Way, Gateway for Cancer, and Research Assistance in Healthcare.
With diverse experience in pharmaceutical, clinical and consumer industries, Mehmood Khan, M.D. brings a wealth of knowledge to his role as Senior Health Advisor at Bloom Health Partners. Currently the Chairman and Chief Executive Officer of Life Biosciences Inc., he provides strategic direction and operational oversight across Life Biosciences and its six daughter companies. His vision of a more efficient and effective drug development pathway will drive innovation in the science and technology that Life Biosciences advances.
Dr. Khan previously served as Chief Scientific Officer and Vice Chairman at PepsiCo, a Fortune 500 company. Prior to joining PepsiCo, Dr. Khan served as President of Takeda Pharmaceuticals, leading the global efforts of one of the largest pharmaceutical companies in the world by revenue. Earlier in his career, Dr. Khan had a distinguished medical career as a faculty member in endocrinology at the Mayo Clinic and Mayo Medical School where he served as Director of the Diabetes, Endocrine and Nutritional Trials Unit.
Dr. Khan is the recipient of numerous distinctions and awards, including The Harris Award for Excellence in Food and Science Technology, a Harvard University Illuminate Global Award for Innovation and was named one of the 100 Most Creative People in Business by Fast Company. Dr. Khan has also held leadership roles on numerous boards and currently serves as Chairman of the U.S. Council on Competitiveness, as a V-Cat Board Member and as a NIST Board Member.
Dr. Khan earned his medical degree from the University of Liverpool Medical School, England and completed a fellowship in clinical endocrinology and nutrition in the Department of Medicine and Food Science and Nutrition at the University of Minnesota, Minneapolis. He is a Fellow of the Royal College of Physicians, London, and a Fellow of the American College of Endocrinology.
Dr. Shepherd is one of the world’s foremost experts in infectious diseases. An associate professor of medicine at Yale School of Medicine, Dr. Shepherd’s global experience include his work as a special advisor to the World Health Organization. His recent history includes advising the Government of India on tuberculosis control, directing a research program in TB and HIV for the Centers for Disease Control and Prevention in Botswana, and assisting the University of Maryland start a large AIDS treatment program in Nigeria.
Honorable, Eric D. Hargan, JD, is the Senior Health Advisor for Bloom Health Partners. He was a Former Deputy Secretary of the United States Department of Health and Human Services. As Deputy Secretary of HHS, the largest department in the federal government, he oversaw the development and approval of all HHS, CMS, and FDA regulations and significant guidances as well as the department’s day-to-day operations and management, and he led policy and strategy development.
Eric served on the board of Operation Warp Speed, where he signed the first document that enabled the start of Operation Warp Speed. This was a public–private partnership initiated by the U.S. government to facilitate and accelerate the development, manufacturing, and distribution of COVID-19 vaccines, therapeutics, and diagnostics.
He also was a Board Member at University Hospitals and Alio Medical, and is a Fellow at the Health Evolution Forum.
Board Certified in Internal Medicine and Infectious Disease, Alexander Stemer, M.D. welcomes the challenge of solving new problems and has been instrumental in the fight against COVID-19, developing infection control programs and protocols for hospitals and skilled nursing facilities.
In addition to serving as Associate Clinical Professor of Medicine at the Indiana University School of Medicine, Dr. Stemer currently serves as the co-chair of the Symphony Health Network COVID-19 Task Force. He also recently worked with the National Institute of Health and Eli Lilly to develop study protocols for prevention and treatment of COVID-19 in skilled nursing facilities using monoclonal antibody. The study was approved by the FDA, completed and recently published in the Journal of the American Medical Association.
Dr. Stemer brings more than 42 years of experience to the Bloom Health Partners team and was recently named the American Heart Association Heart of Gold Executive Chairman for 2022.In addition to serving as Associate Clinical Professor of Medicine at the Indiana University School of Medicine, Dr. Stemer currently serves as the co-chair of the Symphony Health Network COVID-19 Task Force. He also recently worked with the National Institute of Health and Eli Lilly to develop study protocols for prevention and treatment of COVID-19 in skilled nursing facilities using monoclonal antibody. The study was approved by the FDA, completed and recently published in the Journal of the American Medical Association.
Dr. Stemer brings more than 42 years of experience to the Bloom Health Partners team and was recently named the American Heart Association Heart of Gold Executive Chairman for 2022.